America warned it is becoming dangerously reliant on China for new medicines
Por Paul Farrell — – World RSS Feed
America warned it is becoming dangerously reliant on China for new medicines
Proposed framework would focus restrictions on areas like pathogens and potentially weaponizable technologies
Paul Farrell Friday 18 September 2026 13:37 BST
- Bookmark
- Comments Go to comments
Bookmark popover
Removed from bookmarks
Close popover
Your support helps us to tell the story
Read more Support Now
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it’s investigating the financials of Elon Musk’s pro-Trump PAC or producing our latest documentary, ‘The A Word’, which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference. Read more
The Trump administration is considering allowing U.S. pharmaceutical companies to continue striking most licensing deals with Chinese drugmakers despite its broader crackdown on investment in China, according to people briefed on the plans.
Rules being drafted by the Treasury Department would likely allow American drugmakers to invest in promising medicines being developed by Chinese companies, provided they are not linked to pathogens or biotechnology that could potentially be weaponized, three sources told Reuters.
The approach would be considerably looser than restrictions sought by some lawmakers and smaller U.S. biotech companies, which argue that American investment is helping China challenge the U.S. for dominance of the pharmaceutical industry.
open image in galleryThe proposed rules have not been finalized and could still change, particularly if President Donald Trump intervenes, the sources said.
The stakes are enormous. Licensing deals involving Chinese biotech companies were worth $115 billion last year, according to research firm GlobalData, providing U.S. pharmaceutical companies with new drugs for their pipelines while funneling billions of dollars into Chinese firms.
Almost half of U.S. deals to license drugs from overseas in 2025 involved Chinese companies, GlobalData found, with the trend continuing this year.
Pfizer recently announced a collaboration worth up to $10.5 billion with China’s Innovent Biologics covering 12 cancer programs, while Bristol Myers Squibb struck a partnership worth as much as $15.2 billion with Jiangsu Hengrui Pharma.
open image in galleryMajor pharmaceutical companies have been lobbying the Trump administration against sweeping restrictions.
Pfizer CEO Albert Bourla said he had discussed China and national security with Treasury Secretary Scott Bessent, Secretary of State Marco Rubio and officials at the Department of Health and Human Services.
Bourla argued that licensing medicines developed by Chinese companies does not pose a national security threat.
“I don’t think that that’s the way to compete with China, to try to slow them down,” he said.
“The important thing is to have a new medicine, and I don’t see any national security concerns for something like that.”
But some lawmakers and smaller biotech companies are pushing in the opposite direction, warning that continued investment could leave the U.S. strategically dependent on China for new medicines.
open image in gallery“Are we okay with a strategic dependence on China for innovative drugs?” said Ginkgo Bioworks CEO Jason Kelly, who has urged Treasury officials to impose restrictions. “Because that’s what we are currently doing with this offshoring.”
Republican Rep. John Moolenaar and Democratic Rep. Debbie Dingell are among lawmakers seeking tougher restrictions.
Moolenaar has urged Treasury to use the COINS Act, a 2025 national security law restricting some outbound U.S. investment, to clamp down on pharmaceutical transactions involving China.
The pair are also sponsoring legislation that would tighten scrutiny of biotech investments, licensing agreements and joint ventures involving Chinese companies.
Moolenaar has argued that American money flowing into Chinese biotech is helping Beijing move rapidly up the pharmaceutical industry’s value chain.
Other lawmakers disagree.
open image in galleryDemocratic Rep. Jake Auchincloss, whose Massachusetts district includes numerous life-sciences companies, said attempts to contain China’s pharmaceutical industry by restricting American investment were unlikely to succeed.
“China is spending 100 billion dollars on biotechnology. China has brilliant scientists,” he said.
Treasury and the White House declined to comment on the proposed rules.
The deliberations come ahead of Chinese President Xi Jinping’s expected meeting with Trump in the U.S. next week. The new pharmaceutical investment rules are not expected to be unveiled before that meeting, according to people briefed on the process.
More about
Donald TrumpChinaScott BessentMarco RubioDebbie DingellTreasury DepartmentDepartment of Health and Human ServicesXi Jinping
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Most popular
Popular videos
Bulletin
Read next
Fonte: – World RSS Feed
